BFIM
REGN icon

Beese Fulmer Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Beese Fulmer Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-882
Closed -$681K – 472
2026
Q1 		$681K Buy
882
+360
+69% +$276K 0.04% 181
2025
Q4 		$403K Buy
+522
New +$354K 0.03% 232

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Beese Fulmer Investment Management's REGN Position: Q2 2026 in Review

Beese Fulmer Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 882 shares — an estimated $681K sold.

Beese Fulmer Investment Management first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $681K in Q1 2026. 459 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Beese Fulmer Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 882 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $681K.
  • Beese Fulmer Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Beese Fulmer Investment Management's Regeneron Pharmaceuticals position peaked at $681K in Q1 2026.
  • 459 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.